Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: Outcomes by intent to treat analyses

Bone Marrow Transplantation

Volumn 19, Issue 7, 1997, Pages 661-670

  Weaver, C H ^a   West, W H ^a   Schwartzberg, L S ^a   Alberico, T ^a   Leff, R ^a   Greco, F A ^a   Hainsworth, J ^a   Birch, R ^a   McAneny, B ^a   Magee, M ^a   Raefsky, E ^a   Kalman, L ^a   Buckner, C D ^a,b  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

Author keywords

High dose chemotherapy for breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE DISEASE; BREAST CANCER; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DRUG TOXICITY; FEMALE; HEART DISEASE; HUMAN; IMMUNOMODULATION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; SOFT TISSUE DISEASE; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

EID: 0030942012     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700728     Document Type: Article

References (43)

1. Antman K, Ayash L, Elias A et al. A phase II study of highdose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
2. Kennedy MJ, Beveridge RA, Rowley SD et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-926.
3. Williams S, Gilewski T, Mick R, Bitran JD. High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
4. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
5. Weaver C, Birch R, Schwartzberg L, West W. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic Publishers: Boston, 1995, pp 59-85.
6. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
7. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
8. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftmem kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
9. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990; 8: 563-564.
10. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
11. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972; Series A 135: 185-198.
14. Cox DR. Regression models and life-tables. J R Stat Soc 1972; Series B 34: 187-202.
15. Weaver CH, Bensinger WI, Appelbaum K et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
16. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
17. Ahmann FR, Jones SE, Moon TE. The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 1988; 37: 116-122.
18. Houston SJ, Richards MA, Bentley AE et al. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer 1993; 29A: 1513-1518.
19. Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal women: patterns and prognoses. J Clin Oncol 1988; 6: 89-97.
20. Dunphy FR, Spitzer G, Fornoff JE et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Can-cer 1994; 73: 2157-2167.
21. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
22. Seidman AD, Hudis CA, Norton L. Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. Semin Oncol 1995; 22: 3-8.
23. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high anti-tumor effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
24. Ravdin PM, Burris HAI, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-2885.
25. Valero V, Holmes FA, Walters RS et al. Phase II trial of doxetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-2894.
26. Schwartzberg L, Birch R, Weaver C et al. Neoadjuvant chemotherapy with or without paclitaxel and high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support for locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 1996; 15: 124.
27. Holden SA, Teicher BA, Ayash LJ, Frei ER. A preclinical model for sequential high-dose chemotherapy. Cancer Chemother Pharmacol 1995; 36: 61-64.
28. Fennelly D, Schneider J, Spriggs D et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support. J Clin Oncol 1995; 13: 1160-1166.
29. Hudis C, Seidman A, Raptis G et al. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1996; 23: 58-64.
30. Fields KK, Zorsky PE, Hiemenz JW et al. Ifosfamide, carboplatin an etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol 1994; 12: 544-552.
31. Wallerstein R Jr, Spitzer G, Dunphy F et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782-1788.
32. Demirer T, Rowley S, Buckner CD et al. Peripheral blood stem-cell collections after paclitaxel, cyclophosphamide and recombinant human granuloctye colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13: 1714-1719.
33. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
34. Ayash LJ, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa and carboplatin. J Clin Oncol 1996; 14: 2984-2992.
35. Bitran JD, Samuels B, Klein L et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 17: 157-162.
36. Broun ER, Sridhara R, Sledge GW et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13: 2050-2055.
37. Ghalie R, Williams SF, Valentino LA et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995; 1: 40-46.
38. Norton L. Salvage chemotherapy of breast cancer (review). Semin Oncol 1994; 21: 19-24.
39. MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol lmmunother 1993; 36: 215-222.
40. Benyunes MC, Massumoto C, Higuchi C et al. Interleukin-2 ± lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
41. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517-526.
42. Verma U, Charak B, Rajagopal C, Mazumder A. Interleukin-2 in bone marrow transplantation. In: Buckner CD, Clift RA (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic Publishers: Boston, 1995, pp 315-336.
43. Riddell SR, Greenberg PD. Cellular adoptive immunotherapy after bone marrow transplantation. In: Buckner CD, Clift R (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic Publishers: Boston, 1995, pp 337-369.